Trial Profile

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms TEAM

Most Recent Events

09 Jun 2023 This trial has been completed in Germany, according to European Clinical Trials Database record. (13 Mar 2023)
24 Mar 2023 Status changed from recruiting to completed.
25 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com